Illinois Municipal Retirement Fund Raises Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Illinois Municipal Retirement Fund boosted its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 2.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 26,964 shares of the company’s stock after buying an additional 591 shares during the quarter. Illinois Municipal Retirement Fund owned approximately 0.06% of Pacira BioSciences worth $910,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of PCRX. SG Americas Securities LLC increased its holdings in Pacira BioSciences by 37.7% during the third quarter. SG Americas Securities LLC now owns 21,843 shares of the company’s stock valued at $670,000 after buying an additional 5,979 shares during the period. Exchange Traded Concepts LLC purchased a new position in Pacira BioSciences during the third quarter valued at approximately $466,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Pacira BioSciences by 33.8% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,946 shares of the company’s stock valued at $336,000 after buying an additional 2,764 shares during the period. Inspire Investing LLC increased its holdings in Pacira BioSciences by 26.5% during the third quarter. Inspire Investing LLC now owns 9,930 shares of the company’s stock valued at $305,000 after buying an additional 2,083 shares during the period. Finally, Gradient Investments LLC grew its holdings in Pacira BioSciences by 3.3% in the third quarter. Gradient Investments LLC now owns 105,226 shares of the company’s stock worth $3,228,000 after purchasing an additional 3,317 shares during the last quarter. 99.73% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Gary W. Pace sold 1,066 shares of the firm’s stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $29.67, for a total value of $31,628.22. Following the sale, the director now directly owns 140,384 shares in the company, valued at approximately $4,165,193.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Gary W. Pace sold 1,066 shares of the stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $29.67, for a total value of $31,628.22. Following the transaction, the director now directly owns 140,384 shares of the company’s stock, valued at approximately $4,165,193.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Gary W. Pace sold 90,000 shares of the firm’s stock in a transaction on Friday, March 8th. The stock was sold at an average price of $30.60, for a total transaction of $2,754,000.00. Following the transaction, the director now directly owns 22,127 shares in the company, valued at $677,086.20. The disclosure for this sale can be found here. Company insiders own 6.60% of the company’s stock.

Pacira BioSciences Stock Performance

Shares of PCRX stock opened at $26.33 on Monday. The firm’s 50 day moving average price is $28.71 and its 200-day moving average price is $29.63. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.17 and a current ratio of 5.24. Pacira BioSciences, Inc. has a one year low of $25.33 and a one year high of $48.60. The firm has a market cap of $1.22 billion, a P/E ratio of 32.51 and a beta of 0.76.

Pacira BioSciences (NASDAQ:PCRX) last released its earnings results on Thursday, February 29th. The company reported $0.71 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.71. The company had revenue of $181.24 million for the quarter, compared to analyst estimates of $180.60 million. Pacira BioSciences had a net margin of 6.22% and a return on equity of 12.81%. As a group, equities research analysts predict that Pacira BioSciences, Inc. will post 2.18 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on PCRX shares. Royal Bank of Canada cut their price target on shares of Pacira BioSciences from $53.00 to $45.00 and set an “outperform” rating on the stock in a report on Friday, March 1st. Wedbush reaffirmed an “outperform” rating and issued a $57.00 price target on shares of Pacira BioSciences in a report on Thursday, February 8th. JPMorgan Chase & Co. started coverage on shares of Pacira BioSciences in a report on Thursday, March 7th. They issued an “overweight” rating and a $45.00 price target on the stock. TheStreet raised shares of Pacira BioSciences from a “d+” rating to a “c” rating in a report on Thursday, February 29th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $57.00 price target on shares of Pacira BioSciences in a report on Monday, March 4th. Eleven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Pacira BioSciences presently has an average rating of “Buy” and an average price target of $49.50.

Pacira BioSciences Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.